BrainsWay Ltd.
BrainsWay Ltd.
Your view on BWAY
Overview
What the company does, where it operates, and who runs it.
About BrainsWay Ltd.
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Hadar Levy
- Headquarters
- Bynet Building, Jerusalem, IL
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Hadar Levy
- Headquarters
- Bynet Building, Jerusalem, IL
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally.
It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BrainsWay Ltd., and the rating behind it. BWAY last traded at $13.93, 57.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BrainsWay Ltd.. Starting points for BrainsWay Ltd.: P/E 57.9, EPS $0.47, beta 0.15 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BrainsWay Ltd.. BrainsWay Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BrainsWay Ltd.. Trailing twelve-month EPS for BrainsWay Ltd. stands at $0.47. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BrainsWay Ltd.. BrainsWay Ltd. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BrainsWay Ltd. valued side by side against its closest peers. BrainsWay Ltd. is measured against Medical - Specialties peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BrainsWay Ltd., and how their positions are changing. At a $546.4M market value, institutional positions materially move BrainsWay Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BrainsWay Ltd. executives and directors. Shares of BrainsWay Ltd. have traded between $7.84 and $17.92 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BrainsWay Ltd.. BrainsWay Ltd. is a $546.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BrainsWay Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BrainsWay Ltd.. Coverage tracks BrainsWay Ltd. within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.